Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 2/20 | 0.51 |
| ▸ | RXRA | P19793 | 2/20 | 0.48 |
| ▸ | RXRB | P28702 | 2/20 | 0.48 |
| ▸ | RXRG | P48443 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530061 | 0.91 | MRGPRX4 (0.53) | MRGPRX4MAOBHTR2CSLC6A4HTR2B | |
| SCHEMBL769653 | 0.86 | XDH (0.57) | MRGPRX4MAOBXDH | |
| SCHEMBL10469104 | 0.82 | MAOB (0.68) | MAOBXDH | |
| SCHEMBL379218 | 0.81 | MAOB (0.60) | MAOBXDH | |
| SCHEMBL22937898 | 0.81 | MRGPRX4 (0.71) | MRGPRX4MAOB | |
| SCHEMBL24969559 | 0.80 | MAOB (0.60) | MRGPRX4MAOBSLC6A4 | |
| SCHEMBL30152232 | 0.80 | MAOB (0.60) | MRGPRX4MAOBSLC6A4 | |
| SCHEMBL1331639 | 0.79 | HTR2C (0.58) | MRGPRX4HTR2CSLC6A4HTR2BRXRA | |
| SCHEMBL1330628 | 0.79 | MAOB (0.62) | MRGPRX4MAOBXDH | |
| SCHEMBL18703359 | 0.79 | MRGPRX4 (0.61) | MRGPRX4HTR2CSLC6A4HTR2BRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040526-B2 | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2534158-B1 | BENZYLPYRROLIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-2534158-A1 | BENZYLPYRROLIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120295899-A1 | BENZYLPYRROLIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-22 | — | — | US | disclosed |
| WO-2011100227-A1 | BENZYLPYRROLIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
| US-3953595-A | Substituted benzoic acid hypolipemic agents | PFIZER INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295899-A1 | BENZYLPYRROLIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | MRGPRX4 60/4885MAOB 4201/4885HTR2C 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.